NASDAQ:OCRX (OCRX) (OCRX) Stock Price, News & Analysis → Watch this FREE trading tutorial while it’s still available (From InvestorPlace) (Ad) Free OCRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$1.79▼$1.7950-Day Range N/A52-Week Range$0.52▼$2.95VolumeN/AAverage Volume1.11 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (OCRX) alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About (OCRX) Stock (NASDAQ:OCRX)Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.Read More Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. OCRX Stock News HeadlinesApril 21, 2024 | nasdaq.comICVT Crosses Critical Technical IndicatorApril 13, 2023 | msn.comCBN’s Cash Redesign Policy Boosting Economic Growth – Sparkle MDMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. March 9, 2023 | msn.comUPDATE 2-German industrial output rises more than expected in JanuaryFebruary 22, 2023 | msn.comFarmworker Hub opening social space for seasonal workersFebruary 22, 2023 | msn.comWalmart Has a Prediction About the Future of Your Food PricesJanuary 27, 2023 | msn.comExperts betting against a bear market for ASX sharesDecember 30, 2022 | msn.comJools Holland Hootnenanny 2022 line-up: Who’s on the New Year’s Eve show and what time it’s on BBC TwoMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. December 30, 2022 | msn.comSingle family residence in San Jose sells for $1.5 millionNovember 22, 2022 | msn.com'I've had the ride of my life': Sue Cleaver delighted to get the boot from I'm a CelebNovember 6, 2022 | msn.comGTA 6 Should Build On The Storytelling Of GTA 4, Not GTA VOctober 26, 2022 | msn.comBringing Cultural Foods to the Family Dinner TableOctober 26, 2022 | msn.comAge Of Empires 25th anniversary confirms Xbox ports and a legendary remasterOctober 10, 2022 | msn.comHow Many Colleges Should I Apply to?September 4, 2022 | thestreet.comOcera (OCRX) Stock Rises on Positive Drug Trial ResultsAugust 18, 2022 | msn.comSarasota deputy cut with 'massive' machete during armed burglary; suspect fatally shot, officials sayAugust 6, 2022 | nasdaq.comHow The Parts Add Up: XLY Targets $193See More Headlines Receive OCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (OCRX) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2017Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:OCRX Previous SymbolNASDAQ:TZYM CUSIPN/A CIK1274644 Webwww.ocerainc.com Phone+1-650-4750158FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesLinda S. Grais M.D. (Age 61)President, Chief Executive Officer, Director Michael Byrnes (Age 38)Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer Stan Bukofzer M.D. (Age 59)Chief Medical Officer Steven P. James (Age 57)Lead Independent Director Willard H. Dere M.D. (Age 63)Director Nina S. Kjellson (Age 40)Independent Director Anne M. VanLent (Age 68)Independent Director Eckard Weber M.D. (Age 66)Independent Director More Executives OCRX Stock Analysis - Frequently Asked Questions How were (OCRX)'s earnings last quarter? (OCRX) (NASDAQ:OCRX) issued its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). What other stocks do shareholders of (OCRX) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (OCRX) investors own include Biopharmx (BPMX), Heat Biologics (HTBX), Neovasc (NVCN), Synergy Pharmaceuticals (SGYP), Imunon (CLSN), LadRx (CYTR), BioLineRx (BLRX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT). This page (NASDAQ:OCRX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (OCRX) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.